{"id":"W4415436310","doi":"10.1007/s13555-025-01555-3","title":"Long-Term Integrated Safety Summary of Ruxolitinib Cream in Phase 3 Clinical Trials of Patients with Vitiligo","year":2025,"lang":"en","type":"article","venue":"Dermatology and Therapy","topic":"melanin and skin pigmentation","field":"Biochemistry, Genetics and Molecular Biology","cited_by":4,"is_retracted":false,"has_abstract":true,"ca_institutions":"Probity Medical Research; University of Toronto","funders":"LEO Pharma; Bausch Health; Kyowa Hakko Kirin; Horizon Therapeutics; Incyte; Dermira; Celltrion; Valeant Pharmaceuticals International; Sanofi; Amgen; Meiji Seika Pharma; Pfizer; Concert Pharmaceuticals; Galderma; Eli Lilly and Company; Bristol-Myers Squibb; GlaxoSmithKline","keywords":"Ruxolitinib; Vitiligo; Clinical trial; Phase (matter); Phases of clinical research","routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0108965,0.0006090469,0.001654016,0.0006068037,0.0003134822,0.00143203,0.0006520812,0.0007834261,0.00201397],"category_scores_gemma":[0.005276366,0.0003113977,0.00270506,0.0007314354,0.0002519092,0.0006640991,0.0004290361,0.001359597,0.0003569623],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0009401046,"about_ca_system_score_gemma":0.001137549,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0004190762,"about_ca_topic_score_gemma":0.001590007,"domain_scores_codex":[0.9966533,0.002061844,0.0003067625,0.0003154846,0.000467862,0.0001948072],"domain_scores_gemma":[0.9950656,0.001134299,0.002326322,0.0002882084,0.000702281,0.0004834031],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.2558259,0.004869117,0.06984127,0.008231145,0.0307939,0.0003003539,0.0003514843,0.003719539,0.03597642,0.0004219304,0.009311143,0.5803578],"study_design_scores_gemma":[0.2254971,0.3204755,0.3729272,0.001667638,0.0270934,0.00163888,0.0002149205,0.00488905,0.0126744,0.0007409828,0.03202739,0.0001535445],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.8784121,0.1003564,0.004495711,0.001638301,0.0002170204,0.003998869,0.005106429,0.0003062134,0.005468905],"genre_scores_gemma":[0.9772773,0.01161988,0.002829406,0.001127297,0.0002515643,0.001961099,0.003866117,0.00003662148,0.001030819],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.0108965,"threshold_uncertainty_score":0.0576269,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02731667975241602,"score_gpt":0.3794274668762527,"score_spread":0.3521107871238366,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}